Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Established in 1971, Streck provides solutions that ensure every result counts by empowering clinical and research laboratories to reliably deliver accurate results, advance diagnostics and enable healthier, happier lives for patients everywhere.
Seegene Inc., a global leader in multiplex PCR diagnostics, introduces CURECA™, a fully automated PCR platform offering true end-to-end automation from sample loading to result interpretation.
Sebia is a global leader in specialized in vitro diagnostics, providing instruments and reagents for screening and monitoring diseases in Oncology (Multiple Myeloma), Diabetes, Hemoglobinopathies, Autoimmune and Infectious diseases, and other rare disorders.
Polymedco’s mission is to save lives through early detection of life-threatening diseases like colorectal cancer and cardiac diseases by partnering with healthcare systems, payors, providers, and reference labs to build effective screening and early detection programs.
Meet HORIBA in Chicago at the 2025 ADLM, Booth #328. HORIBA designs, develops and distributes worldwide, in vitro diagnostic systems mainly destined for biological analysis in medical laboratories.
HemoSonics’ Quantra® Hemostasis System is revolutionizing bleeding management with its next-generation whole-blood viscoelastic analyzer.
Epredia is a global leader in the anatomical pathology field, providing comprehensive solutions for precision cancer diagnostics and tissue diagnostics. Powered by key brands, including Erie Scientific, Menzel-Gläser, Microm, Shandon, and Richard-Allan Scientific,
ARKRAY has a long-standing history with fully automated urine chemistry and sediment analysis. Hundreds of urinalysis systems are placed throughout the USA. The new ARKRAY AUTION Bridge (AUTION Eye AI-4510 + AUTION Max AX-4060) is a fully automated, walk
ARK Diagnostics, Inc. is committed to improving health care through the design, development, manufacture and distribution of in vitro diagnostic (IVD) immunoassays for therapeutic drug monitoring (TDM), urine drug testing (UDT) and other small molecules. Our focus is the production of high quality, convenient, cost-effective products for routine use in research and clinical practice.
